AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27155880 — intervention group
Group type: COMPARATOR
Intervention: General Health Promotion DVD (HP)
Number of subjects: 170
Study 24832191 — intervention group
Group type: EXPERIMENTAL
Intervention: BAl (4.8 g day(‐1) for 4 weeks, increased to 6.4 g day(‐1) for 2 weeks)
Number of subjects: 8
Study 24832191 — intervention group
Group type: COMPARATOR
Intervention: Pl (CaCO3)
Number of subjects: 8
Study 24832191 — intervention group
Group type: EXPERIMENTAL
Intervention: BAl and SB co-ingestion
Number of subjects: 8
Study 24832191 — intervention group
Group type: COMPARATOR
Intervention: Pl‐SB
Number of subjects: 8
Study 22877888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive exposure (IE)
Number of subjects: 76
Study 22877888 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 76
Study 22877888 — intervention group
Group type: COMPARATOR
Intervention: CBT-based stress-management treatment (SM)
Number of subjects: 76
Study 20977639 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 100
Study 20977639 — intervention group
Group type: COMPARATOR
Intervention: Mini-incision open donor nephrectomy (MIDN)
Number of subjects: 100
Study 19023834 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Number of subjects: 406
Study 19023834 — intervention group
Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 406
Study 16087836 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom prism spectacles incorporating bilateral prisms to match participants' preferred power and base direction
Number of subjects: 225
Study 16087836 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard prism spectacles incorporating standard bilateral prisms (6 prism diopters base up for logMAR VA of 0.48-1.00 and 10 Delta base up for logMAR VA of 1.02-1.68)
Number of subjects: 225
Study 16087836 — intervention group
Group type: COMPARATOR
Intervention: Placebo spectacles matched in weight and thickness to prism spectacles but without prism
Number of subjects: 225
Study 12144195 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies using quantitative, epidemiological methods (nonrandomized trials, cohort studies, case control methods)
Number of subjects: 0
Study 12144195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical database
Number of subjects: 0
Study 10327079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostagene
Number of subjects: 60
Study 10327079 — intervention group
Group type: COMPARATOR
Intervention: Helistat
Number of subjects: 60
Study 7866977 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefits scale (summated Likert format)
Number of subjects: 581
Study 7866977 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers scale (summated Likert format)
Number of subjects: 581
Study 2017326 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate coagulation spots (average: 300 mW)
Number of subjects: 12
Study 2017326 — intervention group
Group type: COMPARATOR
Intervention: Intense coagulation spots (average: 600 mW)
Number of subjects: 12
Study 6886969 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine as aqueous oral solution
Number of subjects: 16
Study 6886969 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine as intravenous infusion over 30 min
Number of subjects: 16
Study 6886969 — intervention group
Group type: COMPARATOR
Intervention: Caffeine elimination rate constant
Number of subjects: 16
Study 6886969 — intervention group
Group type: COMPARATOR
Intervention: Apparent volume of distribution
Number of subjects: 16
Study 6886969 — intervention group
Group type: COMPARATOR
Intervention: Clearance of caffeine
Number of subjects: 16
Study 30658460 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat albumin (WA) 1.5 g
Number of subjects: 0
Study 30658460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 28915861 — intervention group
Group type: EXPERIMENTAL
Intervention: PRODECIDE education program
Number of subjects: 216
Study 28915861 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 216
Study 26345338 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone therapy (4 weeks, oral administration)
Number of subjects: 22
Study 26345338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 weeks, oral administration)
Number of subjects: 22
Study 23974801 — intervention group
Group type: EXPERIMENTAL
Intervention: ART + Carisolv® gel
Number of subjects: 81
Study 23974801 — intervention group
Group type: COMPARATOR
Intervention: ART (conventional ART technique)
Number of subjects: 81
Study 22695473 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d) plus Twelve Step Facilitation (TSF)
Number of subjects: 112
Study 22695473 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d) plus standard counseling
Number of subjects: 112
Study 22695473 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Twelve Step Facilitation (TSF)
Number of subjects: 112
Study 22695473 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard counseling
Number of subjects: 112
Study 22695473 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d)
Number of subjects: 112
Study 22695473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 19282833 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 553
Study 17580147 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg by intravenous infusion 2 hours before operation)
Number of subjects: 118
Study 17580147 — intervention group
Group type: COMPARATOR
Intervention: Control (no induction therapy)
Number of subjects: 118
Study 17580147 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 118
Study 17580147 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 118
Study 17580147 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab and Control
Number of subjects: 118
Study 15837256 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aldosteronism (PA)
Number of subjects: 124
Study 15837256 — intervention group
Group type: COMPARATOR
Intervention: Essential hypertension (EHT)
Number of subjects: 124
Study 11886767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(2) and D(3) combined therapy for 24 months
Number of subjects: 172
Study 11886767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(2) therapy alone for 24 months
Number of subjects: 172
Study 11886767 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving dietary therapy alone
Number of subjects: 172
Study 10334534 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT), n = 39
Number of subjects: 319
Study 10334534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormones), n = 280
Number of subjects: 319
Study 8547939 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% glucose solution (CHO)
Number of subjects: 9
Study 8547939 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (PL)
Number of subjects: 9
Study 2041284 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidan
Number of subjects: 37
Study 2041284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7030036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 78
Study 7030036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 30841568 — intervention group
Group type: EXPERIMENTAL
Intervention: Red and processed meat intake
Number of subjects: 1038
Study 30841568 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroid anti-inflammatory drugs (NSAIDs) use
Number of subjects: 1038
Study 30841568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene variant CCAT2 rs6983267
Number of subjects: 1038
Study 30841568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene variant TP53 rs1042522
Number of subjects: 1038
Study 27322597 — intervention group
Group type: EXPERIMENTAL
Intervention: Guarana 50 mg twice a day during chemoradiotherapy
Number of subjects: 60
Study 27322597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25881590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga foetida extract (Group A)
Number of subjects: 96
Study 25881590 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate and medroxyprogesterone acetate (Group B)
Number of subjects: 96
Study 25881590 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate and progesterone (Group C)
Number of subjects: 96
Study 23551027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture group (speech and gesture)
Number of subjects: 184
Study 23551027 — intervention group
Group type: COMPARATOR
Intervention: Control group (only speech)
Number of subjects: 184
Study 21716983 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate solution used twice daily for 3 months
Number of subjects: 127
Study 19699918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion at 4 cc/hour for 100 hours
Number of subjects: 124
Study 19699918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution) infusion
Number of subjects: 124
Study 19699918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion
Number of subjects: 124
Study 30872289 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS2 (with delirium included)
Number of subjects: 71379
Study 12921544 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives accompany laboring women throughout the birth process until two hours after delivery (n = 3,437)
Number of subjects: 6758
Study 12921544 — intervention group
Group type: COMPARATOR
Intervention: Traditional management with intermittent midwife visits (n = 3,321)
Number of subjects: 6758
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective surgical repair of abdominal aortic aneurysm
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum creatinine level
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower forced expiratory volume in 1 s (FEV1)
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, serum creatinine level, and FEV1
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with below average creatinine levels and above average FEV1
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with above average creatinine levels and below average FEV1
Number of subjects: 820
Study 10848851 — intervention group
Group type: EXPERIMENTAL
Intervention: Published clinical prediction rule
Number of subjects: 820
Study 9356531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate deprivation for 24 hours (one-third of baseline carbohydrate intake)
Number of subjects: 7
Study 9356531 — intervention group
Group type: COMPARATOR
Intervention: High-fat food intake
Number of subjects: 7
Study 9116627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55
Study 9116627 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 55
Study 9116627 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 3898670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (8 mg for adults, 50 mg for schoolchildren, 24 mg for kindergarten children) administered orally every 8 days during the epidemic period (January-March 1983)
Number of subjects: 1811
Study 3898670 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1811
Study 29743334 — intervention group
Group type: EXPERIMENTAL
Intervention: High water (HW) intake based on an individualised water intake prescription
Number of subjects: 50
Study 29743334 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AW) water intake
Number of subjects: 50
Study 29743334 — intervention group
Group type: EXPERIMENTAL
Intervention: High water (HW) intake
Number of subjects: 50
Study 26467700 — intervention group
Group type: EXPERIMENTAL
Intervention: Relamorelin, 100 μg, SQ
Number of subjects: 18
Study 26467700 — intervention group
Group type: COMPARATOR
Intervention: Placebo SQ
Number of subjects: 18
Study 25241324 — intervention group
Group type: EXPERIMENTAL
Intervention: Best endovascular therapy
Number of subjects: 0
Study 25241324 — intervention group
Group type: COMPARATOR
Intervention: Best open surgical treatment
Number of subjects: 0
Study 21474566 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (upper canines)
Number of subjects: 16
Study 21474566 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrew group (miniscrew implants)
Number of subjects: 16
Study 21474566 — intervention group
Group type: COMPARATOR
Intervention: Control group (upper second premolars)
Number of subjects: 16
Study 19960205 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication combined with posterior gastropexy (group A)
Number of subjects: 82
Study 19960205 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication without posterior gastropexy (group B)
Number of subjects: 82
Study 18413295 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CRT (CRT+)
Number of subjects: 23
Study 16002776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount, moderate intensity exercise (walking 12 miles/wk at 40‐55% of peak oxygen consumption)
Number of subjects: 175
Study 16002776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amount, vigorous intensity exercise (jogging 12 miles/wk at 65‐80% of peak oxygen consumption)
Number of subjects: 175
Study 16002776 — intervention group
Group type: EXPERIMENTAL
Intervention: High amount, vigorous intensity exercise (jogging 20 miles/wk)
Number of subjects: 175
Study 16002776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 175
Study 12634266 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride/carbamazepine (A)
Number of subjects: 127
Study 12634266 — intervention group
Group type: COMPARATOR
Intervention: clomethiazole (B)
Number of subjects: 127
Study 12634266 — intervention group
Group type: COMPARATOR
Intervention: diazepam (C)
Number of subjects: 127
Study 12634266 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride/carbamazepine (D) in intoxicated patients
Number of subjects: 127
Study 11083486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutin supplementation (500 mg)
Number of subjects: 18
Study 11083486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose equivalent)
Number of subjects: 18
Study 8633816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (zidovudine with didanosine or zalcitabine)
Number of subjects: 1077
Study 8633816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential monotherapy (with didanosine or zalcitabine)
Number of subjects: 1077
Study 8633816 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 1077
Study 1997702 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment (150 micrograms ethinyl estradiol daily and 80 mg polyestradiol monthly)
Number of subjects: 163
Study 1997702 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 163
Study 1997702 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 163
Study 6150275 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 30
Study 6150275 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy and placebo
Number of subjects: 30
Study 31809265 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional oral medications (0, 1, or 2+ medications)
Number of subjects: 699
Study 31809265 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 699
Study 31809265 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) in girls
Number of subjects: 699
Study 31809265 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 699
Study 30022356 — intervention group
Group type: EXPERIMENTAL
Intervention: If I Were Jack intervention, teacher-delivered, focused on male and female responsibility in preventing unintended pregnancies
Number of subjects: 831
Study 30022356 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 831
Study 27044941 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with traditional osteotomies
Number of subjects: 59
Study 27044941 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 59
Study 27044941 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery with PRF
Number of subjects: 59
Study 27044941 — intervention group
Group type: COMPARATOR
Intervention: Traditional burs (Control group)
Number of subjects: 59
Study 23346871 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone (AT)
Number of subjects: 34
Study 23346871 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen allogeneic bone (AL)
Number of subjects: 34
Study 23346871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AT and AL)
Number of subjects: 34
Study 22858210 — intervention group
Group type: EXPERIMENTAL
Intervention: high-stress condition (social evaluation)
Number of subjects: 68
Study 22858210 — intervention group
Group type: COMPARATOR
Intervention: low-stress condition (control)
Number of subjects: 68
Study 20547760 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched intervention
Number of subjects: 226
Study 20547760 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 226
Study 18720573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management education programme (7 sessions, 15 hours)
Number of subjects: 81
Study 15656907 — intervention group
Group type: COMPARATOR
Intervention: Conservative care protocol (visits with a hand therapist, exercises, self-care booklet, work modification/activity restriction, B6 therapy, ultrasound, possible steroid injections)
Number of subjects: 200
Study 15656907 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (endoscopic vs. open, determined by the surgeon)
Number of subjects: 200
Study 15656907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Conservative care and Surgery)
Number of subjects: 200
Study 12022708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 12022708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10363856 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored leukocyte-reduced RBCs (n = 18)
Number of subjects: 46
Study 10363856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh nonleukocyte-reduced RBCs (n = 17)
Number of subjects: 46
Study 10363856 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontransfused preterm infants, n = 11)
Number of subjects: 46
Study 7724172 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2‐mm incision
Number of subjects: 200
Study 7724172 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0‐mm incision
Number of subjects: 200
Study 7724172 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0‐mm incision
Number of subjects: 200
Study 1782100 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU sCT intramuscularly (i.m.)
Number of subjects: 12
Study 1782100 — intervention group
Group type: COMPARATOR
Intervention: 110 IU sCT intranasally (i.n.)
Number of subjects: 12
Study 1782100 — intervention group
Group type: COMPARATOR
Intervention: 200 IU sCT intranasally (i.n.)
Number of subjects: 12
Study 1782100 — intervention group
Group type: COMPARATOR
Intervention: 400 IU sCT intranasally (i.n.)
Number of subjects: 12
Study 1782100 — intervention group
Group type: COMPARATOR
Intervention: Control day (no treatment)
Number of subjects: 12
Study 6116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 138
Study 6116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 138
Study 6116084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 30626939 — intervention group
Group type: EXPERIMENTAL
Intervention: DLK1 overexpression via adenovirus gene delivery
Number of subjects: 221
Study 30626939 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DLK1 extracellular domain (rDLK1-EC)
Number of subjects: 221
Study 30626939 — intervention group
Group type: COMPARATOR
Intervention: Blockade of Notch signaling using neutralizing antibody or pharmaceutical inhibitor
Number of subjects: 221
Study 28353593 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming infusion (fluid warmed to 35°C)
Number of subjects: 64
Study 28353593 — intervention group
Group type: COMPARATOR
Intervention: Control (room temperature infusion at 22-23°C)
Number of subjects: 64
Study 26514332 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal spray (500 IU, delivering 1000 IU in two spray shots)
Number of subjects: 40
Study 26514332 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule (1000 IU)
Number of subjects: 40
Study 23313567 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes
Number of subjects: 23
Study 23313567 — intervention group
Group type: COMPARATOR
Intervention: No inotropes
Number of subjects: 23
Study 20688437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin reactivity measured in response to a laboratory task
Number of subjects: 0
Study 20688437 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels of oxytocin or cortisol reactivity
Number of subjects: 0
Study 19301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lipid measurements
Number of subjects: 2368
Study 19301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group analysis
Number of subjects: 2368
Study 19301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender analysis
Number of subjects: 2368
Study 19301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level analysis
Number of subjects: 2368
Study 19301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic variation
Number of subjects: 2368
Study 19301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for demographic factors
Number of subjects: 2368